CY1124756T1 - Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας - Google Patents
Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειαςInfo
- Publication number
- CY1124756T1 CY1124756T1 CY20211100980T CY211100980T CY1124756T1 CY 1124756 T1 CY1124756 T1 CY 1124756T1 CY 20211100980 T CY20211100980 T CY 20211100980T CY 211100980 T CY211100980 T CY 211100980T CY 1124756 T1 CY1124756 T1 CY 1124756T1
- Authority
- CY
- Cyprus
- Prior art keywords
- immunodeficiency virus
- human immunodeficiency
- neutralizing antibodies
- virus neutralizing
- methods
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 230000036436 anti-hiv Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει νέα αντισώματα κατά του HIV με βελτιωμένες θεραπευτικές ιδιότητες, σχετικές φαρμακευτικές συνθέσεις και μεθόδους χρήσης αυτών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267652P | 2015-12-15 | 2015-12-15 | |
PCT/US2016/066658 WO2017106346A2 (en) | 2015-12-15 | 2016-12-14 | Human immunodeficiency virus neutralizing antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124756T1 true CY1124756T1 (el) | 2022-07-22 |
Family
ID=58737847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100980T CY1124756T1 (el) | 2015-12-15 | 2021-11-10 | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας |
Country Status (37)
Country | Link |
---|---|
US (3) | US10239935B2 (el) |
EP (2) | EP3390441B1 (el) |
JP (4) | JP6732915B2 (el) |
KR (1) | KR102165120B1 (el) |
CN (2) | CN109311967B (el) |
AR (1) | AR106991A1 (el) |
AU (3) | AU2016370591C1 (el) |
BR (1) | BR112018012164A2 (el) |
CA (1) | CA3008442C (el) |
CL (1) | CL2018001587A1 (el) |
CO (1) | CO2018006050A2 (el) |
CR (1) | CR20180321A (el) |
CU (1) | CU20180062A7 (el) |
CY (1) | CY1124756T1 (el) |
DK (1) | DK3390441T3 (el) |
DO (2) | DOP2018000146A (el) |
EA (2) | EA202091898A1 (el) |
EC (1) | ECSP18045028A (el) |
ES (1) | ES2897756T3 (el) |
HU (1) | HUE056243T2 (el) |
IL (1) | IL259832B (el) |
LT (1) | LT3390441T (el) |
MA (1) | MA44077A (el) |
MX (2) | MX2018007288A (el) |
MY (2) | MY196200A (el) |
NZ (1) | NZ743713A (el) |
PE (1) | PE20181451A1 (el) |
PH (1) | PH12018501281A1 (el) |
PL (1) | PL3390441T3 (el) |
SA (1) | SA518391778B1 (el) |
SG (2) | SG10202108793TA (el) |
SI (1) | SI3390441T1 (el) |
SV (1) | SV2018005710A (el) |
TW (2) | TWI735491B (el) |
UA (1) | UA125819C2 (el) |
WO (1) | WO2017106346A2 (el) |
ZA (1) | ZA201803783B (el) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
KR20170123308A (ko) | 2014-12-26 | 2017-11-07 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
WO2017074878A1 (en) | 2015-10-25 | 2017-05-04 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
WO2017106346A2 (en) | 2015-12-15 | 2017-06-22 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
RS64771B1 (sr) | 2016-04-13 | 2023-11-30 | Sanofi Sa | Trispecifični i/ili trovalentni vezujući proteini |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
PT3443006T (pt) | 2017-03-17 | 2023-10-26 | Sanofi Sa | Proteínas de ligação triespecíficas e/ou trivalentes |
EP3642229A1 (en) | 2017-06-21 | 2020-04-29 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
BR122022008466B1 (pt) | 2017-12-07 | 2023-12-05 | Emory University | Uso de um composto |
PE20201339A1 (es) * | 2017-12-19 | 2020-11-25 | Univ Rockefeller | Variantes de dominio de fc de igg humana con funcion efectora mejorada |
AU2019226034A1 (en) * | 2018-02-21 | 2020-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 Env and their use |
US11845788B2 (en) * | 2018-05-22 | 2023-12-19 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (HIV) |
CN112334572A (zh) * | 2018-06-19 | 2021-02-05 | 南特细胞公司 | Hiv治疗组合物和方法 |
JP7126573B2 (ja) | 2018-07-03 | 2022-08-26 | ギリアード サイエンシーズ, インコーポレイテッド | HIV gp120を標的化する抗体および使用方法 |
EP3849607A4 (en) * | 2018-09-13 | 2022-06-22 | Children's National Medical Center | CELLS COMPRISING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF PREPARING THEM AND USE THEREOF |
WO2020086782A1 (en) * | 2018-10-24 | 2020-04-30 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
EP4292659A3 (en) * | 2018-12-19 | 2024-03-20 | Humabs Biomed SA | Antibodies that neutralize hepatitis b virus and uses thereof |
CN113518823A (zh) * | 2019-01-07 | 2021-10-19 | 托马斯杰斐逊大学 | 多功能的融合蛋白及其用途 |
KR20210142711A (ko) | 2019-03-22 | 2021-11-25 | 길리애드 사이언시즈, 인코포레이티드 | 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도 |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
KR20220047977A (ko) * | 2019-07-08 | 2022-04-19 | 캘리포니아 인스티튜트 오브 테크놀로지 | 감소된 다중 반응성을 갖는 항-hiv 백신 항체 |
CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
TW202200161A (zh) | 2020-03-20 | 2022-01-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
WO2021207635A1 (en) * | 2020-04-09 | 2021-10-14 | The George Washington University | Prussian blue nanoparticles functionalization with latency reversing agents and broadly neutralizing antibodies, and applications thereof |
JP2023539196A (ja) | 2020-08-25 | 2023-09-13 | ギリアード サイエンシーズ, インコーポレイテッド | Hivを標的とする多重特異性抗原結合分子及び使用方法 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
US20230000973A1 (en) * | 2021-06-25 | 2023-01-05 | Janssen Vaccines & Prevention B.V. | Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment |
TW202342448A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
WO2023102239A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5913521B2 (ja) | 1975-06-19 | 1984-03-30 | メイトウサンギヨウ カブシキガイシヤ | 磁性酸化鉄・デキストラン複合体の製造法 |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4454106A (en) | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
PT81498B (pt) | 1984-11-23 | 1987-12-30 | Schering Ag | Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US7041293B1 (en) | 1990-04-03 | 2006-05-09 | Genentech, Inc. | HIV env antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
ATE490788T1 (de) | 2003-04-25 | 2010-12-15 | Gilead Sciences Inc | Antivirale phosphonate analoge |
CA2553946C (en) | 2004-02-06 | 2019-02-26 | University Of Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
EP1778251B1 (en) | 2004-07-27 | 2011-04-13 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti hiv agents |
AU2005302416A1 (en) | 2004-10-29 | 2006-05-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2587617C (en) | 2004-11-12 | 2011-02-01 | Xencor, Inc. | Fc variants with altered binding to fcrn |
WO2006135919A2 (en) | 2005-06-13 | 2006-12-21 | Cargill, Incorporated | Objective methods of estimating age of animals and carcasses |
TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
EP1803814A1 (en) | 2005-12-27 | 2007-07-04 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Method of improving the antibody selection capacity in phage-display library |
WO2008140579A2 (en) | 2006-11-17 | 2008-11-20 | New York University | Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
JP4783325B2 (ja) | 2007-04-09 | 2011-09-28 | 株式会社神戸製鋼所 | 高温排ガスの処理方法 |
US7968544B2 (en) | 2007-06-29 | 2011-06-28 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
CN101918365B (zh) | 2007-11-16 | 2013-10-09 | 吉联亚科学股份有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
CA2732437C (en) | 2008-08-01 | 2017-11-21 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
WO2010056898A2 (en) | 2008-11-12 | 2010-05-20 | University Of Maryland, Baltimore | Rapid expression cloning of human monoclonal antibodies from memory b cells |
ES2623794T3 (es) | 2008-12-09 | 2017-07-12 | Gilead Sciences, Inc. | Intermedios para la preparación de moduladores de receptores tipo toll |
EP2398496B1 (en) | 2009-02-20 | 2015-08-05 | International AIDS Vaccine Initiative | Vesicular stomatitis virus vectors encoding hiv env epitopes |
SI3260136T1 (sl) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa |
EP2246364A1 (en) | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
DK2467377T3 (en) | 2009-08-18 | 2017-04-03 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
AU2010284241B2 (en) | 2009-08-18 | 2016-11-10 | Array Biopharma, Inc. | Substituted benzoazepines as Toll-like receptor modulators |
NO2491035T3 (el) | 2009-10-22 | 2018-01-27 | ||
WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
CN102374226A (zh) | 2010-08-06 | 2012-03-14 | 深圳富泰宏精密工业有限公司 | 套筒、铰链结构及应用该铰链结构的便携式电子装置 |
PT3556396T (pt) | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Anticorpos neutralizantes do vírus da imunodeficiência humana (vih) |
CA2812826C (en) | 2010-09-28 | 2016-07-19 | Fujitsu Limited | Method and base station, user equipment and system for activating coexistence work mode |
US20120219615A1 (en) | 2010-10-01 | 2012-08-30 | The Trustees Of The University Of Pennsylvania | Therapeutic Use of a TLR Agonist and Combination Therapy |
RU2587061C2 (ru) | 2010-10-01 | 2016-06-10 | Вентиркс Фармасьютикалз, Инк. | Способы лечения аллергических заболеваний |
KR101416437B1 (ko) | 2010-11-03 | 2014-07-10 | 한국전자통신연구원 | 파장 가변 외부 공진 레이저 발생 장치 |
KR20140000275A (ko) | 2010-11-18 | 2014-01-02 | 예일 유니버시티 | 인체 면역결핍 바이러스에 대해 항체 모집 및 진입 저해 활성을 갖는 2작용기의 분자 |
PL2663550T4 (pl) | 2011-01-12 | 2017-07-31 | Ventirx Pharmaceuticals, Inc. | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
PL2663555T4 (pl) | 2011-01-12 | 2017-08-31 | Ventirx Pharmaceuticals, Inc. | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
WO2012106578A1 (en) * | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
RS60191B1 (sr) | 2011-04-08 | 2020-06-30 | Janssen Sciences Ireland Unlimited Co | Derivati pirimidina za tretman virusnih infekcija |
UA111841C2 (uk) | 2011-04-21 | 2016-06-24 | Гіліад Сайєнсіз, Інк. | Сполуки бензотіазолу та їх фармацевтичне застосування |
SI2709989T1 (en) | 2011-05-18 | 2018-04-30 | Janssen Sciences Ireland Uc | Quinazoline derivatives for the treatment of viral infections and other diseases |
PT2729448E (pt) | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
US9399645B2 (en) | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
EP2794565B1 (en) | 2011-12-21 | 2017-07-26 | Novira Therapeutics Inc. | Hepatitis b antiviral agents |
JP6283320B2 (ja) | 2012-02-08 | 2018-02-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体 |
PE20141558A1 (es) | 2012-04-20 | 2014-11-06 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih |
US11149069B2 (en) | 2012-08-03 | 2021-10-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers |
BR112015002524B1 (pt) | 2012-08-10 | 2021-11-03 | Janssen Sciences Ireland Uc | Derivados de alquilpirimidina, composição farmacêutica que os compreende e uso dos mesmos |
TR201807076T4 (tr) | 2012-10-10 | 2018-06-21 | Janssen Sciences Ireland Uc | Viral enfeksiyonların ve diğer hastalıkların tedavisine yönelik pirolo[3,2-d]pirimidin derivatları. |
EP2925729B1 (en) | 2012-11-16 | 2017-10-18 | Janssen Sciences Ireland UC | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
EP2940019B1 (en) | 2012-12-27 | 2018-03-28 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR |
WO2014124457A1 (en) * | 2013-02-11 | 2014-08-14 | University Of Louisville Research Foundation, Inc. | Methods for producing antibodies |
KR102300861B1 (ko) | 2013-02-21 | 2021-09-10 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
CA2932405A1 (en) | 2013-12-02 | 2015-06-11 | Aaron Diamond Aids Research Center | Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture |
PL3166607T3 (pl) * | 2014-07-11 | 2023-02-20 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych do leczenia hiv |
PT3321265T (pt) | 2015-03-04 | 2020-07-07 | Gilead Sciences Inc | Compostos 4,6-diamino-pirido[3,2-d]pirimidina compounds e a sua utilização como moduladores de receptores do tipo toll |
WO2017106346A2 (en) | 2015-12-15 | 2017-06-22 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
-
2016
- 2016-12-14 WO PCT/US2016/066658 patent/WO2017106346A2/en active Application Filing
- 2016-12-14 CN CN201680079823.5A patent/CN109311967B/zh active Active
- 2016-12-14 SI SI201631372T patent/SI3390441T1/sl unknown
- 2016-12-14 CA CA3008442A patent/CA3008442C/en active Active
- 2016-12-14 CR CR20180321A patent/CR20180321A/es unknown
- 2016-12-14 EA EA202091898A patent/EA202091898A1/ru unknown
- 2016-12-14 KR KR1020187019806A patent/KR102165120B1/ko active IP Right Grant
- 2016-12-14 PE PE2018001115A patent/PE20181451A1/es unknown
- 2016-12-14 TW TW105141486A patent/TWI735491B/zh active
- 2016-12-14 UA UAA201806361A patent/UA125819C2/uk unknown
- 2016-12-14 SG SG10202108793TA patent/SG10202108793TA/en unknown
- 2016-12-14 EA EA201891186A patent/EA201891186A1/ru unknown
- 2016-12-14 CU CUP2018000062A patent/CU20180062A7/es unknown
- 2016-12-14 HU HUE16867376A patent/HUE056243T2/hu unknown
- 2016-12-14 SG SG11201804787UA patent/SG11201804787UA/en unknown
- 2016-12-14 EP EP16867376.2A patent/EP3390441B1/en active Active
- 2016-12-14 LT LTEPPCT/US2016/066658T patent/LT3390441T/lt unknown
- 2016-12-14 EP EP21192543.3A patent/EP3992206A1/en active Pending
- 2016-12-14 MY MYPI2021003644A patent/MY196200A/en unknown
- 2016-12-14 JP JP2018530831A patent/JP6732915B2/ja active Active
- 2016-12-14 MY MYPI2018702243A patent/MY186414A/en unknown
- 2016-12-14 DK DK16867376.2T patent/DK3390441T3/da active
- 2016-12-14 AR ARP160103833A patent/AR106991A1/es unknown
- 2016-12-14 MX MX2018007288A patent/MX2018007288A/es unknown
- 2016-12-14 BR BR112018012164A patent/BR112018012164A2/pt active Search and Examination
- 2016-12-14 US US15/379,157 patent/US10239935B2/en active Active
- 2016-12-14 MA MA044077A patent/MA44077A/fr unknown
- 2016-12-14 CN CN202210281565.6A patent/CN114848812A/zh active Pending
- 2016-12-14 TW TW110130315A patent/TWI814056B/zh active
- 2016-12-14 ES ES16867376T patent/ES2897756T3/es active Active
- 2016-12-14 NZ NZ743713A patent/NZ743713A/en unknown
- 2016-12-14 AU AU2016370591A patent/AU2016370591C1/en active Active
- 2016-12-14 PL PL16867376T patent/PL3390441T3/pl unknown
-
2018
- 2018-06-05 IL IL259832A patent/IL259832B/en unknown
- 2018-06-07 ZA ZA2018/03783A patent/ZA201803783B/en unknown
- 2018-06-11 SA SA518391778A patent/SA518391778B1/ar unknown
- 2018-06-13 SV SV2018005710A patent/SV2018005710A/es unknown
- 2018-06-13 CL CL2018001587A patent/CL2018001587A1/es unknown
- 2018-06-13 EC ECIEPI201845028A patent/ECSP18045028A/es unknown
- 2018-06-13 CO CONC2018/0006050A patent/CO2018006050A2/es unknown
- 2018-06-13 DO DO2018000146A patent/DOP2018000146A/es unknown
- 2018-06-14 PH PH12018501281A patent/PH12018501281A1/en unknown
- 2018-06-14 MX MX2022013524A patent/MX2022013524A/es unknown
-
2019
- 2019-02-12 US US16/273,753 patent/US10882898B2/en active Active
- 2019-12-05 AU AU2019275625A patent/AU2019275625B2/en active Active
-
2020
- 2020-05-14 JP JP2020085079A patent/JP6936361B2/ja active Active
- 2020-12-03 US US17/110,876 patent/US11655285B2/en active Active
-
2021
- 2021-01-29 DO DO2021000022A patent/DOP2021000022A/es unknown
- 2021-08-26 JP JP2021137876A patent/JP7126594B2/ja active Active
- 2021-11-04 AU AU2021261910A patent/AU2021261910B2/en active Active
- 2021-11-10 CY CY20211100980T patent/CY1124756T1/el unknown
-
2022
- 2022-08-16 JP JP2022129584A patent/JP2022163192A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
CY1122329T1 (el) | Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων | |
CY1123570T1 (el) | Τροποποιητες πυρηνικης πρωτεϊνης ηπατιτιδας β | |
CY1124252T1 (el) | Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου | |
CY1124004T1 (el) | Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους | |
CY1123996T1 (el) | Υποκατεστημενα παραγωγα οξοπυριδινης | |
CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
CL2017003261A1 (es) | Factor xi anticuerpos y métodos de uso | |
EA201790630A1 (ru) | Способы получения рибозидов | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
BR112017010177A2 (pt) | composição para tratamento de tecido | |
CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
CY1121187T1 (el) | Ενα εκχυλισμα απο indigo naturalis και μια διεργασια για την παρασκευη εκεινου | |
PE20161210A1 (es) | Anticuerpos anti-mcam y metodos de uso asociados | |
EA201790495A1 (ru) | Фармацевтические композиции длительного действия | |
CY1124748T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν δοραβιρινη, φουμαρικη δισοπροξιλη τενοφοβιρης και λαμιβουδινη | |
UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
MX2017002093A (es) | Terapia con anticuerpos para vih como sustituto de tratamiento. | |
EA201790771A1 (ru) | Фармацевтические композиции длительного действия для лечения гепатита c | |
PH12018500645A1 (en) | Hiv antibody compositions and methods of use | |
JOP20180058A1 (ar) | أجسام مضادة محيدة لفيروس نقص المناعة البشرية | |
CY1121388T1 (el) | Παραγωγα βενζυλυδροξειδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων | |
TH1501003876A (th) | วัคซีนของไทรเมอร์ของถุงหุ้ม (Env) ของไวรัสโรคภูมิคุ้มกันบกพร่องของ มนุษย์ซึ่งทำให้เกิดเสถียรภาพ (HIV) และวิธีการของการใช้ที่เหมือนกัน |